PRECISION BIOSCIENCES INC (DTIL)
Health Care · Gene editing / genome editing therapeutics · NASDAQ
Precision BioSciences is a clinical-stage gene editor developing ARCUS-based in vivo therapies targeting hepatitis B, muscular dystrophy, and rare genetic diseases.
What PRECISION BIOSCIENCES INC does
Precision BioSciences is a clinical-stage gene editing company that develops in vivo therapies for genetic and infectious diseases using its proprietary ARCUS genome editing platform. ARCUS is a natural homing endonuclease that enables precise gene editing through insertion, excision, and elimination. The company currently has two lead clinical programs: PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, plus a partnered program with iECURE for OTC deficiency.
Themes: ["gene editing / genome editing","in vivo therapy","hepatitis B treatment","Duchenne muscular dystrophy (DMD)","mitochondrial disease","genetic diseases","rare genetic disorders"]
Fundamentals
- Price$9.16 as of 2026-07-09 close
- Market cap$231M as of 2026-07-10
- 1-year return+93.7% as of 2026-07-09 close
- Net margin-96.7% as of 2026-07-10
- ROE-79.6% as of 2026-07-10
- Debt / equity0.29 as of 2026-07-10
- Revenue growth (YoY)-11.9% as of 2026-07-10
- Revenue CAGR (3y)+10.9% SEC XBRL
- Beta1.27 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: both lead programs (PBGENE-HBV and PBGENE-DMD) are in early-stage clinical trials with uncertain efficacy and safety outcomes that could delay or prevent regulatory approval","Competitive gene editing landscape: other genome editing technologies (CRISPR, base editors, prime editors) are advancing in parallel, with established competitors potentially capturing market share before ARCUS therapies reach commercialization","High cash burn and unprofitability: company is unprofitable with net margin of -96.73%, requiring significant continued funding to advance clinical programs through development and potential regulatory approval"]
Competitors & peers
- Editas Medicine (NASDAQ: EDTA)
- CRISPR Therapeutics (NASDAQ: CRSP)
- Beam Therapeutics (NASDAQ: BEAM)
- Sangamo Therapeutics (NASDAQ: SGMO)
- Intellia Therapeutics (NASDAQ: NTLA)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.